IDEAYA Biosciences, Inc.
NASDAQ:IDYA · NASDAQ Global Select
-$0.45 today
Vol 1.48M · Avg 1.44M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$113.7M +58.6% | -$274.5M -143.0% | -$113.0M -92.6% | -$58.7M -17.9% | -$49.8M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $4.6M +19.8% | $3.8M -4.3% | $4.0M +90.8% | $2.1M +21.8% | $1.7M | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $46.1M +32.7% | $34.7M +87.9% | $18.5M +59.0% | $11.6M +41.2% | $8.2M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | $1.9M -83.8% | $11.5M +187.4% | -$13.2M +68.2% | -$41.6M -133.3% | -$17.8M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | $0 -100.0% | $15.0K -92.2% | $193.0K -78.4% | $892.0K +15.2% | $774.0K | $592.6M | $1.3B | $626.2M |
| Inventory | $0 | $0 | $0 | $0 -100.0% | $3.8M | $1.0B | $1.2B | $1.1B |
| Accounts Payables | $2.7M -67.4% | $8.3M +214.2% | $2.6M +41.4% | $1.9M +59.9% | $1.2M | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | -$829.0K -125.5% | $3.3M +120.3% | -$16.0M +63.8% | -$44.3M -88.2% | -$23.5M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | -$10.0M +57.1% | -$23.2M -101.1% | -$11.6M -1562.3% | -$695.0K -137.9% | $1.8M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | -$71.1M +71.3% | -$247.6M -114.9% | -$115.2M -32.2% | -$87.2M -56.3% | -$55.8M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$2.4M +38.6% | -$3.9M -62.9% | -$2.4M +31.2% | -$3.4M -30.2% | -$2.6M | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $0 | $0 | $0 -100.0% | $33.4M -50.2% | $67.0M | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | -$607.9M +49.0% | -$1.2B -99.9% | -$596.0M -133.0% | -$255.8M +18.8% | -$315.0M | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $680.2M -1.8% | $692.6M +57.4% | $439.9M +94.8% | $225.8M -8.9% | $248.0M | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | $0 | $0 | $0 +100.0% | -$33.4M +50.2% | -$67.0M | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | $70.0M +113.9% | -$502.6M -217.2% | -$158.5M -374.4% | -$33.4M +52.1% | -$69.7M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | $0 | $0 | $0 | $0 | $0 | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $29.8M -95.4% | $654.2M +111.2% | $309.8M +226.2% | $95.0M -33.7% | $143.3M | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | $0 -100.0% | $13.9M +29.2% | $10.8M +389.0% | $2.2M +0.1% | $2.2M | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | $29.8M -95.6% | $677.6M +86.8% | $362.7M +273.3% | $97.2M -33.2% | $145.5M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | -$210.0K | $0 | $0 | $0 | $0 | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | $28.4M +139.2% | -$72.6M -181.5% | $89.0M +480.3% | -$23.4M -217.0% | $20.0M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | -$73.5M +70.8% | -$251.4M -113.8% | -$117.6M -29.8% | -$90.6M -55.1% | -$58.4M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Cogent Biosciences, Inc.
NASDAQ:COGT
$5.88B
Scholar Rock Holding Corporation
NASDAQ:SRRK
$5.63B
Cidara Therapeutics, Inc.
CDTX
$5.61B
Legend Biotech Corporation
NASDAQ:LEGN
$5.30B
Amicus Therapeutics, Inc.
FOLD
$4.55B
Kiniksa Pharmaceuticals, Ltd.
NASDAQ:KNSA
$4.13B
Beam Therapeutics Inc.
NASDAQ:BEAM
$3.40B
Adaptive Biotechnologies Corporation
NASDAQ:ADPT
$2.79B
Zai Lab Limited
NASDAQ:ZLAB
$2.09B
Mineralys Therapeutics, Inc.
NASDAQ:MLYS
$1.69B
SEC Filings
Recent regulatory filings
No filings found.
Does IDYA generate free cash flow?
IDEAYA Biosciences, Inc. (IDYA) generated -$73,466,000.00 of free cash flow in fiscal 2025.
How much operating cash flow does IDYA produce?
Operating cash flow was -$71,098,000.00, before capital expenditures of $2.37M.
Explore More
Continue the stock analysis
Jump to another research area for this company.